Table 2.
Solicited adverse events within 7 days after injections (safety analysis set).
| First injection |
Second injection |
Any injection |
||||
|---|---|---|---|---|---|---|
| n (%) | mRNA-1273 (N = 150) |
Placebo (N = 50) |
mRNA-1273 (N = 147) |
Placebo (N = 50) |
mRNA-1273 (N = 150) |
Placebo (N = 50) |
| Any solicited adverse event | 138 (92.0) | 12 (24.0) | 135 (91.8) | 11 (22.0) | 144 (96.0) | 19 (38.0) |
| Maximum severity | ||||||
| Grade 1 | 106 (70.7) | 11 (22.0) | 42 (28.6) | 10 (20.0) | 44 (29.3) | 17 (34.0) |
| Grade 2 | 26 (17.3) | 0 | 47 (32.0) | 1 (2.0) | 51 (34.0) | 1 (2.0) |
| Grade 3 | 6 (4.0) | 1 (2.0) | 45 (30.6) | 0 | 48 (32.0) | 1 (2.0) |
| Grade 4 | 0 | 0 | 1 (0.7) | 0 | 1 (0.7) | 0 |